Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457935 | 0.81 | POLB (0.54) | CYP11B1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7510438 | 0.80 | ALDH1A1 (0.64) | CHRNB2CHRNA4CYP11B1GABRA1GABRA5 | |
| SCHEMBL1768170 | 0.80 | POLB (0.61) | LMNAHDAC8HDAC6KDM4EL3MBTL1 | |
| SCHEMBL27383596 | 0.78 | LMNA (0.46) | CYP11B1LMNAPOLBMAPK1 | |
| Hydrochloric Acid SCHEMBL9523272 | 0.78 | KDM4E (0.60) | HDAC8HDAC6KDM4EL3MBTL1POLB | |
| SCHEMBL9752787 | 0.78 | POLB (0.63) | KDM4EL3MBTL1POLBNPSR1 | |
| SCHEMBL19513465 | 0.78 | KLKB1 (0.53) | GABRA1GABRA5LMNAL3MBTL1POLB | |
| SCHEMBL16881377 | 0.77 | KLKB1 (0.40) | CYP11B1LMNAL3MBTL1POLBNPSR1 | |
| SCHEMBL9752676 | 0.77 | POLB (0.58) | LMNAKDM4EL3MBTL1POLBNPSR1 | |
| SCHEMBL18569859 | 0.76 | ALDH1A1 (0.48) | CHRNB2CHRNA4CYP11B1LMNAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748622-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-114732910-B | P38 kinase inhibitors reduce DUX4 and downstream gene expression and treat FSHD | 弗尔康医疗公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114748622-A | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | 弗尔康医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114732910-A | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20190142813-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2019-05-16 | — | — | US | disclosed |
| US-10058541-B2 | Multisubstituted aromatic compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180064698-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2018-03-08 | — | — | US | disclosed |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
| US-20170258775-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9687479-B2 | Multisubstituted aromatic compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170065570-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-03-09 | — | — | US | disclosed |
| EP-2991981-B1 | DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9533970-B2 | Multisubstituted aromatic compounds as serine protease inhibitors | VERSEON CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160024047-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2016-01-28 | — | — | US | disclosed |
| WO-2014177469-A1 | DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142813-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CHRNB2 3520/4885CHRNA4 3325/4885CYP11B1 2791/4885 |
| US-20180064698-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SERPINE1, PRSS1, SPINT2 | CHRNB2 4643/4885CHRNA4 4699/4885CYP11B1 2550/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | CHRNB2 3520/4885CHRNA4 3325/4885CYP11B1 2791/4885 |
| US-10058541-B2 | Multisubstituted aromatic compounds as serine protease inhibitors | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
| US-20160024047-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
| US-20170065570-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | CHRNB2 3520/4885CHRNA4 3325/4885CYP11B1 2791/4885 |
| US-20170258775-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, SERPINB1 | CHRNB2 4787/4885CHRNA4 4879/4885CYP11B1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.